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Abstract
Background
Botulinum neurotoxins (BoNTs) are considered to be the most toxic substances known on
earth and are responsible for human botulism, a life-threatening disease characterized by
flaccid muscle paralysis that occurs naturally by food-poisoning or colonization of the gas-
trointestinal tract by BoNT-producing clostridia. BoNTs have been classified as category A
agent by the Centers of Disease Control and Prevention (CDC) and are listed among the six
agents with the highest risk to be used as bioweapons. Neutralizing antibodies are required
for the development of effective anti-botulism therapies to deal with the potential risk of
exposure.
Results
In this study, a macaque (Macaca fascicularis) was immunized with recombinant light chain
of BoNT/E3 and an immune phage display library was constructed. After a multi-step pan-
ning, several antibody fragments (scFv, single chain fragment variable) with nanomolar
affinities were isolated, that inhibited the endopeptidase activity of pure BoNT/E3 in vitro by
targeting its light chain. Furthermore, three scFv were confirmed to neutralize BoNT/E3
induced paralysis in an ex vivomouse phrenic nerve-hemidiaphragm assay. The most
effective neutralization (20LD50/mL, BoNT/E3) was observed with scFv ELC18, with a mini-
mum neutralizing concentration at 0.3 nM. Furthermore, ELC18 was highly effective in vivo
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when administered as an scFv-Fc construct. Complete protection of 1LD50 BoNT/E3 was
observed with 1.6 ng/dose in the mouse flaccid paralysis assay.
Conclusion
These scFv-Fcs antibodies are the first recombinant antibodies neutralizing BoNT/E by tar-
geting its light chain. The human-like nature of the isolated antibodies is predicting a good
tolerance for further clinical development.
Introduction
Botulism is a potentially life-threatening disease associated with foodborne poisoning caused
by intoxication with botulinum neurotoxins (BoNTs) that are secreted by Clostridium botuli-
num and certain other Clostridium spp. or by colonization of the gastrointestinal tract by
BoNT-producing clostridia. It is characterized by flaccid and life-threatening muscle paralysis
that requires long term treatment in intensive care unit [1,2]. To date, 7 serologically distinct
serotypes (designated A to G) of BoNT are known. Four BoNT serotypes (A, B, E, rarely F) are
responsible for most cases of human botulism [3]. In the past, several cases of botulism caused
by BoNT/A, B and E have been reported worldwide [4–8]. BoNT/F causes only 1% of food poi-
soning-related cases of botulism, including adult toxin coinfections [9]. Due to their high toxic-
ity, BoNTs are classified as category A agents by the Centers for Disease Control and
Prevention (CDC) and as a group are among the six agents with the highest risk of potential
use as bioweapons [10,11]. The Soviet Union and Iraq were suspected of weaponizing BoNTs
and the Japanese cult AUM Shinrikyo attempted to use BoNT for bioterrorism [12,10,13]. Fur-
thermore, the risk of deliberate contamination of the food chain by BoNTs has been
highlighted by several incidents [14].
Clostridium spp. producing botulinum neurotoxin E (BoNT/E) are found in aquatic sedi-
ments and intoxications are reported mainly in North European, American and Asian regions
where fish are smoked or frequently eaten without cooking [15]. BoNT/E-related intoxications
are more scarce than those related to BoNT/A and BoNT/B, but the median lethal dose 50
(LD50) of BoNT/E is estimated to be as low as that of BoNT/A, equal to 1.1 ng/kg in mice and
monkeys (by intravenous, subcutaneous and intraperitoneal route) [16]. To date, twelve
BoNT/E subtypes (E1 to E12) have been identified based on sequence analysis [17].
All BoNT serotypes are synthesized as a 150 kDa single-chain progenitor toxin which is sub-
sequently activated by a clostridial protease to generate a disulfide bond-linked structure con-
taining a 50 kDa light chain and a 100 kDa heavy chain. The heavy chain contains two
functional domains (Hc and Hn) that are required for toxin uptake into nerve cells by recep-
tor-mediated endocytosis and for the translocation of the light chain across the membrane into
the neuronal cytosol. In a final step, the catalytic domain of the light chain (a zinc endopepti-
dase), cleaves the SNARE complex proteins (soluble N-ethylmaleimide-sensitive factor attach-
ment protein receptor) which are involved in the fusion of synaptic vesicles with the
presynaptic membrane and inhibits neurotransmitter release, thereby causing flaccid paralysis,
which requires intensive hospitalization [18]. Contrary to other BoNT serotypes, BoNT/E, pro-
duced by group II C. botulinum strains, is secreted by clostridia as a unique inactive chain that
requires activation by host proteases for toxicity. This process, called nicking, is associated with
a 100-fold increase in toxicity [19,20]. After BoNT/E binds to specific receptors on the surface
of neurons and following endocytosis and translocation of the light chain into the cytosol, the
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toxin acts on peripheral cholinergic nerve endings, where it cleaves SNAP–25 (synaptosomal-
associated protein 25 kDa) through its zinc metalloprotease activity, targeting specifically
between residues 180 and 181, resulting in the inhibition of acetylcholine release at the neuro-
muscular junction by vesicle exocytosis [21,22].
BoNTs are also used as therapeutics for a multitude of disorders including glandular hyper-
secretion, skeletal or smooth muscle hyperactivity and chronic pain-associated involuntary
muscle conditions [23,24]. Due to the increasing medical uses of BoNTs, widespread vaccina-
tion against botulism would prevent from the benefit of these wide therapeutic applications.
The current approach for treatment of botulism is based on passive immunization with an
equine antitoxin sera consisting of Fab and/or F(ab')2 preparations [25] or in case of infant bot-
ulism with human anti-botulism immunoglobulins, such as BabyBig
1
[26]. Unfortunately, the
quantity of the human serum stock is limited [27] and the equine sera may induce serious
adverse effects, including serum sickness and hypersensitivity [28]. The efficiency of these anti-
toxin treatments is removal of the toxin from the bloodstream before it can be internalized into
neurons and induce a lethal flaccid paralysis. However, these antitoxins are no longer effective
once the toxin is taken up into the neurons which happens faster than the identification of a
botulism case since patients develop symptoms more than 3 days after intoxication. The cur-
rent situation supports the need for new human-like or human antibody preparations that are
highly effective and better tolerated than equine antibodies. However, because BoNT serotypes
differ by up to 70% in their amino acid sequence, it is necessary to neutralize each serotype
with specific antibodies [29].
To develop neutralizing antibodies against BoNT/E, the selection of high affinity antibodies
using non-human primate immune libraries is a promising strategy. Due to the phylogenetic
proximity between non-human primates (NPHs), such as macaques (Macaca fascicularis), and
humans, the use of NHPs makes it possible to isolate human-like antibody fragments for thera-
peutic applications [30]. This strategy has been successfully used for the isolation of several
antibody fragments with nanomolar or picomolar affinities against different antigens of clinical
interest, such as Crf2, a surface antigen of Aspergillus fumigatus [31], viruses like Western
equine encephalitis virus (WEEV) and Venezuelan equine encephalitis virus (VEEV) [32,33]
and several toxins, such as tetanus toxin [34], ricin [35] and the two sub-units of anthrax lethal
toxin [36,37]. In a previous study we isolated several recombinant antibodies targeting the light
chain of BoNT/A, using a macaque immune library, which neutralize the toxicity of BoNT/A
in an ex vivomouse phrenic nerve diaphragm assay [38]. In recently published studies, the epi-
topes of the antibodies generated against BoNT/E were located in the heavy chain. Previously,
seventeen monoclonal antibodies were generated by immunization of BALB/c mice with type
E toxoid, which bound to the heavy chain of BoNT/E [39]. Furthermore, an antibody, scFv
4E17, was isolated from human volunteers immunized with botulinum pentavalent vaccine,
which binds to an epitope located at the N-terminus of the heavy chain [40]. Meng et al.
described a human monoclonal antibody directed against an epitope located on the light chain
of BoNT/E [41]. However, to our knowledge, no recombinant human-like antibody that neu-
tralizes BoNT/E in vivo by targeting the light chain (BoNT/E-L) has been reported to date.
Our strategy for the isolation of BoNT/E-L specific antibody fragments was based on the
immunization of a macaque with recombinant BoNT/E3-L to generate an immune library,
potentially spanning most of the epitopes on the light chain of BoNT/E with high-affinity anti-
bodies, rather than selection of antibodies directed against non-relevant antigens. In this study
we describe the isolation and characterization of several scFv from a non-human antibody
gene library by phage display, focusing on their inhibition of the protease activity of BoNT/E-L
in vitro, the neutralization properties in the mouse ex vivo phrenic nerve model as scFv and
scFv-Fc and in vivo protection in the mouse flaccid paralysis assay.
Neutralizing BoNT/E Antibodies
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Materials and Methods
Ethical statement and animal care
All animal studies described involving the use on non-human primates received specific
approval from the Institut de Recherche Biomédicale des Armées Ethics committee (Comité
d’éthique de l’Institut de Recherche Biomédicale du Service de Santé des Armées) under autho-
rization no. 2008/03.0 and were performed in accordance with all relevant French laws and eth-
ical guidelines, including, in particular (1) “partie règlementaire du livre II du code rural (Titre
I, chapitre IV, section 5, sous-section 3: expérimentation sur l’animal),” (2) “décret 87–848 du
19-10/1987 relatif aux expériences pratiquées sur les animaux vertébrés modifié par le décret
2001/464 du 29/05/2001,” (2) “arrêté du 29 octobre 1990 relatif aux conditions de l’expérimen-
tation animale pour le Ministère de la Défense,” and (4) “instruction 844/DEF/DCSSA/AST/
VET du 9 avril 1991 relative aux conditions de réalisation de l’expérimentation animale.” Ani-
mal care procedures complied with the regulations detailed under the Animal Welfare Act [42]
and in the Guide for the Care and Use of Laboratory Animals [43]. Animals were kept at a con-
stant temperature (22°C ± 2°C) and relative humidity (50%), with 12 h of artificial light per
day. They were housed in individual cages (6 per room), each of which contained a perch. Ani-
mals were fed twice daily, once with dried food and once with fresh fruits and vegetables, and
water was provided at the same time. Food intake and general behavior were observed by the
animal technicians during feeding times and veterinary surgeons were available for consulta-
tion if necessary. Veterinary surgeons also performed regular visits to each NHP-room twice
weekly. The environmental enrichment program for the non-human primates involved games
with animal care staff and access to approved toys. The well-being of the animals was moni-
tored by the attending veterinary surgeon. Animals were anesthetized before the collection of
blood or bone marrow by an intramuscular injection of 10 mg/kg ketamine (Imalgene
1
, Mer-
ial). If the animal technicians suspected that the animal was in pain, on the basis of their obser-
vations of animal behavior, analgesics were subsequently administered, through a single
intramuscular injection of 5 mg/kg flunixine (Finadyne
1
, Schering Plough) in the days after
interventions. None of the non-human primates died during this study.
For the ex vivo phrenic nerve-hemidiaphragm assays male in-bred BALB/c mice supplied
by Harlan (UK) were used. The mice were killed by cervical dislocation prior to test. Death was
then confirmed by severing the jugular blood vessel to ensure permanent cessation of the circu-
lation. For the in vivo paralysis assay female, outbred, strain MF1 mice were used, supplied by
Harlan (UK). The procedure was a refinement of the lethality (LD50) test, as only sub-lethal
doses of toxin were injected into animals and no animal died during the process. The in vivo
paralysis assay was performed at NIBSC by approved procedure covered by the UK Home
Office project license (PPL # 80/2634, holder Dr D Sesardic) for Research on Bacterial Products
used in Medicine. All such experiments complied with the UK Home Office regulations for the
use of animals in research and testing under the Animals (Scientific Procedures) Act 1986
(ASPA) and revised European Directive 2010/63/EU on the protection of animals.
All experiments on animals at NIBSC (UK) were approved by the local animal research
oversight committee AWERB (Animal Welfare and Ethics Review Body, which meets monthly
to review procedures.
Production of Botulinum Neurotoxin E light chain for animal
immunization
DNA encoding the BoNT/E light chain (amino acids 1–420) was PCR amplified from C. botuli-
num E3 strain P34 with primers adding BamHI and SalI restriction sites at the 5' and 3' ends,
Neutralizing BoNT/E Antibodies
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respectively. The DNA fragment was cloned into pET28 vector and the construction was
checked by sequencing. The recombinant plasmid was transferred into E. coli BL21 DE3 strain.
The recombinant E. coli strain was grown in LB medium and was induced at OD600 about 0.8
with IPTG (0.2 mg/mL) and then the culture was incubated at 20°C overnight with vigorous
shacking. The cell pellet was sonicated in PBS with a cocktail of protease inhibitors and BoNT/
E light chain was purified on cobalt column (Talon, Clontech) by elution with imidazole in
PBS. The homogeneity of BoNT/E light chain preparation was checked on SDS-PAGE and
assayed with the BioRad Bradford assay.
Activation of BoNT/E3
BoNT/E3 was purchased as a single chain, and therefore proteolytic activation was performed
prior to use to generate the active form. This also minimized the risk of denaturation of the
activated BoNT/E3. Pure BoNT/E3 holotoxin (Metabiologics Inc.), 3 μg at a concentration of
1 μg/μL in PBS, was incubated for 30 min at 37°C with 0.15 μg trypsin (T1426, Sigma Aldrich).
The cleavage reaction was stopped by adding 0.3 μg (100 μg/mL) trypsin inhibitor (T9003,
Sigma Aldrich) and by incubating the reaction mixture for 30 min at 37°C. The extent of acti-
vation was assessed by capillary electrophoresis under reducing conditions where migration of
a band corresponding to the uncleaved toxin (150 kDa) and the appearance of a 50 kDa and a
100 kDa band (data not shown) were monitored (Experion, Bio-Rad, Hercules, USA).
For in vitro endopeptidase inhibition studies, and ex vivo and in vivo neutralization studies
concentrated pure hemagglutinin free BoNT/E3 at 1 mg/mL (3 x 105 LD50/mg) was purchased
fromMetabiologics Inc. (Lot # E062805-01, strain Alaska). This toxin was trypsinised by using
the method described by Jones et al., 2008 and activity determined as 6 x 107 LD50/mg. After
dilution to 12,560 LD50/mL in 50 mM gelatin (0.2% w/v) phosphate buffer, pH 6.5 toxin was
stored frozen at -80°C and remained stable for several years.
Animal immunization
Amale cynomolgus macaque (Macaca fascicularis) was immunized with five subcutaneous
injections of 80 μg recombinant botulinum neurotoxin light chain (BoNT/E3-L, amino acids
M1 to G420). The first injection of BoNT/E was mixed with complete Freund’s adjuvant
(Sigma, Isle d’ Abeau, France) and for the remaining injections, incomplete Freund’s adjuvant
was used. The three first injections were administered at one-month intervals, the fourth injec-
tion was administered eight months after the third and the fifth was administrated three
months after the fourth (Fig 1). The macaque immune response was evaluated by ELISA per-
formed in 96-well microtiter plates (MaxiSorp, Nunc) using activated BoNT/E3 (2 μg/mL) in
PBS. Pre-immune serum was used as a negative control. For detection, Fc-specific polyclonal
anti-macaque immunoglobulin G (IgG) (Nordimmune, Tilburg, The Netherlands) was used
and the titer was measured as the reciprocal of the highest dilution of immune serum giving a
signal three times stronger than that of the negative control, at the same dilution.
Construction of the anti-BoNT/E3-L scFv antibody library
After the fifth immunization, RNA was isolated with Tri Reagent
1
(TR118, Molecular Research
Center Inc.) from the bone marrow of the immunized macaque and used for reverse transcrip-
tion. Seven oligonucleotides were used for amplification of the DNA encoding the κ light chain
and nine oligonucleotides were used to amplify the DNA encoding Fd fragments of the γ chain
[44]. To obtain two sub-libraries encoding the Fd fragment and κ light chain, the correspond-
ing PCR products were pooled and sub-cloned into the pGEM
1
-T vector (A3600, Promega).
The final library was constructed starting from these two sub-libraries. The DNA encoding the
Neutralizing BoNT/E Antibodies
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Fd fragment and the κ light chain was re-amplified with two individual oligonucleotide sets
introducing the required restrictions sites for library-cloning using the pHAL35 vector. This
vector is based on pHAL32 [38] and was designed for this library. Here, the tag order was
changed from His/Myc to Myc/His, resulting in better expression of scFv in E. coli [45]. First
the pHAL35 vector and the VL-amplified repertoire were digested withMluI and NotI (New
England Biolabs). Afterwards, the enzyme reaction was terminated and the vector was dephos-
phorylated with calf intestinal phosphatase (MBI Fermentas). The vector and the VL-repertoire
were purified using NucleoSpinII Gel and PCR Clean-up Kit (Macherey-Nagel) and 270 ng of
the VL-repertoire was cloned into 1 μg of dephosphorylated vector separately in four ligation
reactions using T4 DNA-Ligase (Promega). The DNA of the ligation product was precipitated
with ethanol and sodium acetate. The pellet was washed twice with 70% ethanol and resus-
pended in 30 μL H2O before it was used for electroporation (1.7 kV) with 25 μL of XL1-Blue
MRF’ (Stratagene). The transformed bacteria were cultured on 2xYT agar plates (25 cm petri
dishes) supplemented with 100 μg/mL ampicillin, 20 μg/mL tetracycline and 100 mM glucose.
The colonies were harvested by resuspension in 40 mL of 2xYT medium with a Drigalsky spat-
ula and plasmids were isolated with the Nucleobond Plasmid Midi Kit (Macherey-Nagel). Fol-
lowing this, the VL-library and the VH-repertoire were digested with SfiI and HindIII (New
England Biolabs), ligated and electroporated as described for VL, but this time 250 ng of the
digested and purified VH-repertoire was inserted into 1 μg of the VL-library. The harvested
bacteria of the final scFv antibody gene library were pooled, aliquoted and stored at -80°C. The
library was packaged with M13K07.
Selection of BoNT/E3-L specific scFv by antibody phage display
For isolation of BoNT/E3-L specific scFv, a microtiter plate was coated overnight with activated
holotoxin BoNT/E3 (Metabiologics Inc.) at 20 μg/mL in PBS at 4°C. The plate was then
blocked with 3% BSA in TBS (50 mM TRIS; 137 mMNaCl; 2.7 mM KCl; pH adjusted to 8.0
with HCl) for 2 h at 37°C. After a washing step, the antibody phage display library was added
and incubated for an additional 2 h at 37°C. During the first round of panning, the plate was
washed 5 times with TBS supplemented with 0.1% Tween20
1
. Each wash consisted of pipetting
up and down five times with an interval of five minutes between washes. The plate was finally
rinsed with sterile TBS and phage were eluted with trypsin (10 mg/mL in TBS) for 30 min at
Fig 1. Schema of macaque immunization. Immunization was performed with five subcutaneous injections of recombinant BoNT/E3 light chain and sera
were sampled to estimate the immunization titer.
doi:10.1371/journal.pone.0139905.g001
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37°C. The eluted phage were used to infect E. coli (SURE strain, Stratagene) cultured in SB
(Super Broth) supplemented with tetracycline (10 μg/mL) and carbenicillin (50 μg/mL). For
the production of new phage particles, infected E. coli were co-infected with M13K07 and cul-
tured overnight at 30°C in SB supplemented with tetracycline (10 μg/mL), carbenicillin (50 μg/
mL) and kanamycin (70 μg/mL). Phage particles were precipitated in PEG/NaCl (4% (w/v)
PEG–8000, 3% (w/v) NaCl) and used for the next round of panning. This was performed as
described above, with the exception that the plate was washed 10 times during the second
round, 20 times during the third and then 40 times in the fourth round, with TBS supple-
mented with 0.1% Tween20
1
and a five-minute interval between washes. The infected E. coli of
the fourth round of panning were grown on SB media in petri dishes and used for screening by
ELISA using activated BoNT/E3 (2 μg/mL).
DNA sequencing and sequence analysis
After screening, one hundred randomly chosen BoNT/E3 specific scFv-producing clones were
sequenced by Beckman Coulter Genomics (Takeley, United Kingdom). All unique sequences
were compared with the human germline genes using the IMGT/V-QUEST and IMGT/
DomainGapAlign online tool from the International ImmunoGeneTics information system
1
(IMGT) (http://www.imgt.org). This tool allows the identification of the human germline
genes most similar to any given variable region and calculates the Germinality Index (GI),
defined as the percentage identity between a given framework (FR) and the most similar
human germline sequence.
Production of soluble scFv or scFv-Fc and measurement of specific
binding and affinity
For expression of soluble scFv, the DNA encoding the selected scFv was used to transform the
non-suppressor E. coli strain HB2151 [46]. Transformed E. coli were then used to inoculate 5
mL of SB (Super Broth) medium supplemented with carbenicillin (50 μg/mL) and 1% glucose.
Cultures were incubated overnight at 30°C with shaking (250 rpm). The following day, 500 mL
of SB medium (50 μg/mL carbenicillin, 1% glucose) was inoculated with the overnight culture
(OD600 ~ 0.1) and cultivated at 30°C until OD600 ~ 1.5. Then, 1 mM IPTG was added to induce
the expression of scFv and the culture was incubated overnight at 22°C. After harvesting by
centrifugation at 2,500 x g for 15 min at 4°C scFv were extracted with polymyxin B sulfate and
purified using a HIS Trap column (GE Healthcare, Buckinghamshire, UK) by a Profinia auto-
mat (Bio-Rad, Hercules, California) according to the manufacturer's instructions. Purified scFv
were quantified using capillary electrophoresis on an Experion device (Bio-Rad).
All scFv fragments were subcloned into pCSE2.5-mIgG2c-Fc-XP (murine Fc part consisted
of CH2 and CH3) and produced as scFv-Fc in HEK293–6E cells [National Research Council
(NRC), Biotechnological Research Institute (BRI)] cultured in chemically defined medium F17
(Invitrogen, Life Technologies) supplemented with 1 g/L pluronic F68 (Applichem), 4 mM L-
glutamine (PAA) and 25 mg/L G418 (PAA), as previously described [47]. DNA was used for
the transient transfection of 25 mL cultures of HEK293–6E cells in 125 mL Erlenmeyer shake
flasks. After 48 h of culture with shaking at 110 rpm in a Minitron orbital shaker (Infors) at
37°C, under an atmosphere containing 5% CO2, one volume of culture medium, with a final
concentration of 0.5% (w/v) tryptone N1 (TN1, Organotechnie S.A.S.) was added and culti-
vated for an additional 3 days. ScFv-Fc were purified with a UNOsphere SUPrA column
(Biorad) using a Profinia apparatus (Biorad, Hercules), according to the manufacturer’s
instructions.
Neutralizing BoNT/E Antibodies
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For ELISA, a microtiter plate was coated overnight with activated holotoxin BoNT/E3
(Metabiologics Inc.) at a concentration of 20 μg/mL in PBS at 4°C. The wells were blocked by
incubation with 2% (w/v) skim milk powder in PBS supplemented with 0.1% Tween20
1
(2%
MPBST) for 1.5 h at room temperature, and washed three times with PBS supplemented with
0.1% Tween20
1
(PBST). Soluble scFv were diluted in 100 μL 2%MPBST and were incubated in
the antigen-coated wells for 1.5 h at room temperature. The wells were then washed three
times with PBST and bound scFv were detected with an anti-His tag antibody (QIAGEN,
Courtaboeuf, France).
Antibody affinity was determined by surface plasmon resonance spectroscopy using a BIA-
core 3000 instrument (GE Healthcare-Biacore, Uppsala, Sweden). ScFv were coated at a maxi-
mum of 800 RU on a CM5 chip (BR100012, GE Healthcare-Biacore) via amine coupling
according to the manufacturer's instructions. A flow rate of 30 μL/min was maintained during
each measurement and volumes of 100 μL of at least ten dilutions of activated BoNT/E3 (250
nM to 0.03 nM) dissolved in HBS-EP buffer (BR100188, GE Healthcare-Biacore) were tested.
After each dilution, the chip was regenerated with 1.5 μM glycine buffer (BR100354, GE
Healthcare-Biacore) injected for 30 s at 10 μL/min. Affinities were calculated using the BIAeva-
luation software (GE Healthcare-Biacore) according to the Langmuir 1:1 adsorption model
and were verified by internal consistency test [48].
In vitro endopeptidase immunoassay
The in vitro endopeptidase immunoassay for BoNT/A and BoNT/E have been reported previ-
ously [49] The assay was modified to assess the inhibitory properties of the scFv and scFv-Fc
[38,50]. For BoNT/E endopeptidase assay synthetic 70 aa SNAP–25 (137–206) peptide sub-
strate was purchased from Immune Systems Ltd (Paignton, UK) and BoNT/E cleavage site spe-
cific antibody (SNAP–25 173–180) was made in house in rabbits and used at 40 μg/mL as
previously described [49]. Inhibition studies were performed to determine the concentrations
at which scFv fragments could inhibit the endopeptidase activity conferred by a fixed concen-
tration of BoNT/E toxin. This was selected as the concentration producing approximately 80–
90% of maximum activity in dose-response study. This was 20LD50/mL (330 pg) for pure holo-
toxin BoNT/E. A range of concentrations of scFv were mixed with an equal volume of 40LD50/
mL of pure holotoxin BoNT/E (75 μL + 75 μL) to give a final concentration of 20LD50/mL (330
pg) of BoNT/E toxin and a range of concentration of scFv (2.58 to 660 nM). The toxin/scFv
mixture was briefly shaken on a plate shaker for 1 min at room temperature and the reaction
mixture was incubated for 1 h at 37°C prior to transfer (50 μL/well) to polystyrene 96 well
ELISA plates coated with SNAP–25 (137–206) peptide for estimation of toxin endopeptidase
activity. All dilutions were made in reaction buffer (50 mMHEPES, 20 μMZnCl2, pH 7.0, 0.5%
(v/v) Tween20
1
, 5 mM DTT) and incubated for 18 h at room temperature. Washes were per-
formed three times with PBS supplemented with 0.05% (v/v) Tween20
1
. Reaction of non-
inhibited BoNT/E toxin on SNAP–25 (137–206) peptide was detected by anti-SNAP–25 (173–
180) antibody at 40 μg/mL diluted in 2.5% (w/v) skimmed milk powder in phosphate buffered
saline (PBS). After 1 h incubation at room temperature, the plate was washed with PBS supple-
mented with 0.05% (v/v) Tween20
1
and 100 μL per well of goat anti-rabbit (Sigma A0545)
detection antibody (1:2000 diluted in 2.5% MPBST) were added and the plate incubated again
for 1.5 h. at room temperature. After washing, 100 μL per well substrate solution (50 mM citric
acid pH 4.0, 0.05% (w/v) ABTS (2,2’-azino-bis(3-ethylben-zothiazoline-6-sulfonic acid) diam-
monium salt, and 0.05% (v/v) of a 30% (w/v) hydrogen peroxide solution) were added and the
staining reaction was evaluated by determining absorbance at 405 nm with a plate reader (Mul-
tiskan MS, Labsystems). To allow meaningful comparison, all scFv antibody fragments were
Neutralizing BoNT/E Antibodies
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diluted to the same initial concentration of 40 μg/mL and doubling serial dilutions were made
from this concentration prior to adding BoNT/E.
Ex vivomouse phrenic nerve-hemidiaphragm assay
Left phrenic nerve-hemidiaphragm preparations were excised from male inbred mice (BALB/
c) and installed in a 6 mL organ bath maintained at 37°C containing Krebs-gelatin buffer
gassed with 95% O2-5% CO2 bubbled through the buffer. Indirect stimulation via the phrenic
nerve was achieved with a supramaximal voltage (~3 V, 1 Hz, 0.2 ms) and the resulting muscle
contractions were measured with an isometric force transducer (FMI GmbH) linked to a
ML110 bridge amplifier and a Powerlab/4SP 4 channel recorder (ADInstruments). The hemi-
diaphragm resting tension was increased in a stepwise manner during the equilibration period,
until reproducible twitches were observed. The toxin was diluted in oxygenated Krebs buffer
and incubated at 37°C for 30 min before being applied to the tissue. Once the muscle twitch
response to nerve stimulation had stabilized and remained of a constant magnitude for at least
30 min without further adjustment, the Krebs buffer was replaced with 6 mL of toxin in Krebs
solution and stimulation was resumed. Toxin-induced paralysis was defined as a 50% decrease
in the muscle twitch response to neurogenic stimulation, based on the magnitude of the con-
tractions just before the addition of the toxin. The time to 50% paralysis after the addition of
BoNT/E3 was determined by fitting to the linear part of the paralysis curve. The myotoxic
effects of the toxin were also assessed by applying a short burst of direct (muscle) stimulation
(~30 V, 1 Hz, 1 ms,) before adding the toxin and at the end of the experiment. Toxin neutrali-
zation by the antibody preparations was assessed by mixing 330 pg/mL (20LD50/mL) pure
BoNT/E3 holotoxin with different concentrations of antibody preparation and incubating for
30 min at 37°C before applying the mixture to the tissue. The toxin dose considered optimal
for antibody inhibition studies is typically that inducing about 80% maximum paralytic activity
on the dose-response curve (ensuring optimal precision), unless further antibody characteriza-
tion requires weaker paralytic activity. The organ bath was drained, the toxin/antibody mixture
was added and twitch responses were recorded for up to 300 min (5 h) or until the twitch ten-
sion was no longer detectable. The time to 50% paralysis after the addition of the mixture of
BoNT/E3 and antibody was determined by fitting to the linear part of the paralysis curve
[51,52]. Linear and nonlinear regression analyses were performed with Prism 5.0 software
(Graphpad). The neutralization of toxin activity was proportional to the ability of the antibody
to delay BoNT-induced paralysis. Greater antibody neutralizing potency was associated with
the requirement of a longer period of time for the hemidiaphragm to reach 50% paralysis for
the same dose of toxin.
In vivo neutralization studies in mouse flaccid paralysis assay
Botulinum toxin induces asymmetric flaccid muscular paralysis at the site of injection and this
has formed the development of an assay for toxin and serotype specific neutralization. The
method was further validated against the mouse LD50 test for neutralization of BoNT/A by spe-
cific IgG and its smaller fragments.
Neutralization activity of scFv-Fc ELC18 (selected as described above) was assessed in vivo
using a range of doses of the antibody (from 1.0 μg per dose). BoNT/E3 toxin (Metabiologics
pure toxin was used at 1LD50 (24 pg) per dose. All dilutions were prepared in gelatin (0.2% w/
v) phosphate (50 mM di-sodium hydrogen orthophosphate) buffer, (GPBS, pH 6.5), and toxin:
antibody mixtures were left for 30 min at room temperature before injecting 0.1 mL subcutane-
ously into female MF1 strain of mice, weighing between 16–20 g (n = 4 per dose). All injections
were performed within 30 min and all the mice were injected in the left inguinocrural region.
Neutralizing BoNT/E Antibodies
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Scores were recorded at 24 h post injection, with intensity of paralysis ranging from 0 (no sign
of paralysis), to scores between 1 and 4, defined by an increasing extent of local flaccid paraly-
sis. A positive control group of mice were injected with BoNT/E3 toxin alone, and a negative
control group of mice were injected with the maximum concentration of antibody used in the
assay in the absence of toxin.
Results
Animal immunization and construction of the antibody phage display
library-cloning
As shown in Fig 1 a male macaque (Macaca fascicularis) was immunized with five injections of
recombinant BoNT/E3 light chain (BoNT/E3-L). Fourteen days after the second injection, the
immune response was evaluated by ELISA using BoNT/E3 holotoxin and a titer equal to
1:300,000 was observed. Three months after the fourth injection, bone marrow was sampled
but no RNA encoding the Fd fragments and the κ light chain were amplified using specific oli-
gonucleotides. Three months after the fourth injection, a fifth injection with BoNT/E3-L was
administered. The bone marrow was iteratively sampled over 17 days, and the bone marrow
sampled at the 10th day after the last immunization provided the optimal amplification of the
DNA encoding the Fd fragments and the κ light chain. The PCR-products were pooled and
sub-cloned into pGEM
1
-T vector to obtain two sub-libraries of 4.1 x 104 and 2.3 x 104 clones
encoding the Fd fragments and κ light chains, respectively. For final construction of the
immune library, the phage display vector pHAL35 was used. This vector is a modified form of
pHAL32 with changed His/Myc-tag orientation, which results in a better production-rate of
soluble scFv [45]. The scFv library was constructed by two consecutive cloning steps. First, the
κ light chain was cloned, usingMluI and NotI, and then the Fd fragments, using SfiI andHin-
dIII. The final scFv antibody gene library consisted of 9.6 x 108 independent clones with a full-
size insert rate of 88%. Finally, the immune library was packaged with M13K07, resulting in
phage titers of 3.4 x 1013 cfu/mL and this was used for antibody selection.
Isolation of BoNT/E3-L specific scFv
Amulti-step panning of four rounds was performed against BoNT/E3 holotoxin with 5, 10, 20
and 40 washes, respectively. After the third round of panning 1.6 x 106 scFv-phage were iso-
lated. After each round of panning, the reactivity of the eluted phage against BoNT/E3 was
assessed by phage-ELISA and the signal increased 1.5-fold between round 1 and 4. In addition,
no reactivity against trypsin and trypsin inhibitor, nor against BSA, KLH and LF was observed
(data not shown). After the fourth round of panning, one hundred scFv-clones were randomly
chosen, the scFv encoding DNA was extracted and sequenced. Only five sequences appeared to
be recombined and the corresponding clones were discarded. Of the 95 remaining scFv, 78
sequences were identified in a single copy and seven were identified in two or more copies,
resulting in a total of 85 different scFv sequences. The diversity was represented in the form of
a phylogenetic tree and at least one sequence from each cluster was selected resulting in the
selection of 38 scFv. After transformation of the DNA in HB2151 all 38 scFv were successfully
expressed and purified.
Analysis of the represented germline genes
After sequencing, analysis using IMGT/V-QUEST tool was performed, to identify the human
germline V, (D), J genes most similar to the 38 selected scFv that were selected for further in
vitro analysis (Table 1). Almost all heavy chain V genes were dominated by the IGHV4 gene
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family, with the exception of 2 occurrences of the IGHV1 and IGHV3 gene family. These genes
were combined with representatives of all IGHD genes and IGHJ genes. The diversity of the
light chain was limited due to the presences of mostly IGKV1 genes with only one occurrence
of IGKV7. These genes were combined with nearly all IGKJ genes. The Germinality Index (GI)
Table 1. Human germline genesmost similar to the genes encoding the BoNT/E3 specific scFv.
scFv VH VL GI [%]
V D J V J VH VL
ELC7 IGHV4-39*07 IGHD2-15*01 IGHJ5*01 IGKV1-17*01 IGKJ4*01 89.0 92.1
ELC8 IGHV4-59*02 IGHD1-26*01 IGHJ4*02 IGKV1-16*01 IGKJ3*01 85.7 84.3
ELC9 IGHV4-39*07 IGHD2-15*01 IGHJ5*01 IGKV1-6*01 IGKJ4*01 87.9 91.0
ELC11 IGHV4-39*07 IGHD3-3*01 IGHJ5*01 IGKV1-17*01 IGKJ2*01 85.7 92.1
ELC12 IGHV4-39*07 IGHD3-22*01 IGHJ5*01 IGKV1-17*01 IGKJ4*01 89.0 94.4
ELC14 IGHV4-28*01 IGHD3-22*01 IGHJ3*01 IGKV1-17*01 IGKJ2*03 86.8 88.8
ELC18 IGHV4-28*01 IGHD2-21*01 IGHJ3*01 IGKV1-9*01 IGKJ2*03 85.7 89.9
ELC20 IGHV3-NL1*01 IGHD1-20*01 IGHJ4*03 IGKV1D-13*01 IGKJ1*01 81.3 87.6
ELC21 IGHV4-39*07 IGHD4-11*01 IGHJ4*02 IGKV1D-16*01 IGKJ3*01 89.0 85.4
ELC22 IGHV4-38-2*01 IGHD2-8*02 IGHJ5*01 IGKV1-17*01 IGKJ4*01 85.7 92.1
ELC24 IGHV4-59*02 IGHD2-2*01 IGHJ4*02 IGKV1-12*01 IGKJ2*03 89.0 83.1
ELC25 IGHV4-39*07 IGHD2-8*02 IGHJ5*01 IGKV1-6*01 IGKJ4*01 85.7 93.3
ELC31 IGHV3-66*02 IGHD2-21*02 IGHJ5*02 IGKV1-5*03 IGKJ3*01 89.0 85.4
ELC32 IGHV4-38-2*01 IGHD2-8*02 IGHJ5*01 IGKV1-17*01 IGKJ4*01 84.6 94.4
ELC37 IGHV4-28*01 IGHD2-21*01 IGHJ3*01 IGKV1-17*01 IGKJ3*01 83.5 89.9
ELC40 IGHV4-59*02 IGHD1-26*01 IGHJ4*02 IGKV1-5*03 IGKJ2*03 85.7 86.5
ELC41 IGHV1-2*02 IGHD5-12*01 IGHJ5*02 IGKV7-3*01 IGKJ3*01 82.4 75.3
ELC45 IGHV4-39*07 IGHD1-26*01 IGHJ5*02 IGKV1-9*01 IGKJ2*03 85.7 91.0
ELC51 IGHV4-39*07 IGHD2-15*01 IGHJ5*01 IGKV1-17*01 IGKJ3*01 89.0 83.2
ELC55 IGHV4-39*07 IGHD1-26*01 IGHJ5*02 IGKV1-9*01 IGKJ2*03 89.0 91.0
ELC58 IGHV4-30-4*07 IGHD6-13*01 IGHJ4*02 IGKV1-12*01 IGKJ2*01 82.4 89.9
ELC62 IGHV4-30-4*07 IGHD6-25*01 IGHJ3*02 IGKV1-12*01 IGKJ4*01 85.7 87.6
ELC63 IGHV4-28*01 IGHD3-22*01 IGHJ5*02 IGKV1-16*01 IGKJ2*03 91.2 91.0
ELC65 IGHV4-28*01 IGHD2-21*02 IGHJ4*02 IGKV1-6*01 IGKJ2*03 91.2 84.3
ELC69 IGHV4-30-4*07 IGHD1-20*01 IGHJ1*01 IGKV1-16*01 IGKJ4*01 94.5 88.8
ELC72 IGHV1-69-2*01 IGHD3-10*01 IGHJ2*01 IGKV1-16*01 IGKJ4*01 84.6 92.1
ELC73 IGHV4-39*07 IGHD2-15*01 IGHJ5*01 IGKV1-17*01 IGKJ2*01 87.9 84.3
ELC76 IGHV4-39*07 IGHD2-15*01 IGHJ5*01 IGKV1-6*01 IGKJ4*01 87.9 94.4
ELC77 IGHV4-30-2*01 IGHD5-12*01 IGHJ1*01 IGKV1-16*01 IGKJ4*01 90.1 91.0
ELC78 IGHV4-4*02 IGHD4-17*01 IGHJ1*01 IGKV1-16*01 IGKJ3*01 89.0 93.3
ELC81 IGHV4-59*02 IGHD3-10*02 IGHJ4*02 IGKV1-12*01 IGKJ4*01 89.0 85.4
ELC88 IGHV4-28*01 IGHD3-9*01 IGHJ4*02 IGKV1-17*01 IGKJ2*01 78.0 91.0
ELC92 IGHV4-30-2*01 IGHD5-12*01 IGHJ1*01 IGKV1-9*01 IGKJ1*01 92.3 92.1
ELC95 IGHV4-30-2*01 IGHD5-24*01 IGHJ4*02 IGKV1-12*01 IGKJ3*01 84.6 92.1
ELC96 IGHV4-39*07 IGHD4-11*01 IGHJ4*02 IGKV1-12*01 IGKJ3*01 89.0 93.3
ELC97 IGHV4-4*02 IGHD1-1*01 IGHJ5*01 IGKV1-39*01 IGKJ4*01 85.7 87.6
ELC103 IGHV4-28*01 IGHD3-22*01 IGHJ3*01 IGKV1-9*01 IGKJ2*03 86.8 94.4
ELC109 IGHV4-30-4*07 IGHD6-13*01 IGHJ4*02 IGKV1-16*01 IGKJ2*03 81.3 93.3
The human germline genes most similar to the genes encoding the 38 selected scFv were identified by IMGT/V-QUEST analyses. The Germinality Index
(GI) of each scFv (VH and VL) was calculated using IMGT/DomainGapAlign.
doi:10.1371/journal.pone.0139905.t001
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for each VH and VL was calculated using IMGT/DomainGapAlign and provided an indication
of the identity between framework regions of the selected scFv and those encoded by the most
similar human germline genes, as a percentage. The average GI-values for all 38 scFv were
86.9% (VH) and 89.4% (VL).
In vitro endopeptidase immunoassay
The 38 selected scFv were assessed for their inhibition capacities in the SNAP–25 endopepti-
dase immunoassay. Four scFv effectively inhibited BoNT/E3 holotoxin with antibody concen-
trations producing 50% BoNT/E3 inhibition (IC50 values) of 33.8 nM (ELC76), 49.1 nM
(ELC77), 58.6 nM (ELC51) and 112.8 nM (ELC18), respectively (Fig 2, Table 2) (The raw data
for Figs 2–5 are given in S1 File). The most potent inhibitor, ELC76, inhibited the endopepti-
dase activity of BoNT/E3 at a molar ratio of scFv to toxin of 14,765:1 (IC50 of 33.8 nM)
(Table 2). The scFv inhibiting toxin endopeptidase activity were selected for further analyses
using the ex vivomouse phrenic nerve-hemidiaphragm assay and affinity measurement.
Affinity measurement
The affinity of the four scFv that inhibited the endopeptidase activity of BoNT/E3 was deter-
mined by surface plasmon resonance spectroscopy. All affinities were in the sub-nanomolar
range from 0.01 nM (ELC77) to 9.16 nM (ELC51) (Table 3). The four selected scFv did not
react against trypsin or trypsin-inhibitor (data not shown). These antigens were used as con-
trols as they were part of the antibody selection process for toxin activation. No correlation was
observed between affinity and IC50.
Fig 2. In vitro endopeptidase assay.Concentration-dependent inhibition of the endopeptidase activity of
BoNT/E3 holotoxin (330 pg/mL; 20LD50/mL) in vitro by several scFv targeting the light chain of BoNT/E3. As
control, SNAP–25 cleavage by BoNT/E3 without inhibiting scFv and buffer without toxin. Each data point is a
mean of triplicate determinants from two separate experiments (n = 6) ± SEM.
doi:10.1371/journal.pone.0139905.g002
Table 2. Inhibition of BoNT/E3 endopeptidase activity.
scFv Antibody concentration for 50% endopeptidase inhibition (IC50)
[nM]
Molar ratio scFv:
toxin
ELC18 112.8 49,214
ELC51 58.6 25,571
ELC76 33.8 14,765
ELC77 49.1 21,428
doi:10.1371/journal.pone.0139905.t002
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Ex vivomouse phrenic nerve-hemidiaphragm assay
To confirm that the antibodies that inhibited the endopeptidase activity of BoNT/E3 in vitro
also have toxin neutralization properties, their neutralization capacity against 20LD50/mL
BoNT/E3 was tested at a concentration of 165 nM in the ex vivomouse phrenic nerve-hemi-
diaphragm assay (Fig 3A, Table 4). Only ELC18, ELC51 and ELC76 were tested ex vivo.
Sequence analysis of ELC77 showed a glycosylation site and it was discarded from further
development. As controls phrenic nerve-hemidiaphragm preparations incubated in Krebs with
or without BoNT/E3 were used for negative and positive comparison of the antibody induced
Fig 3. Ex vivomouse phrenic nerve-hemidiaphragm assay. A) Neutralization of BoNT/E3 holotoxin (330 pg/mL; 20LD50/mL) by 165 nM scFv. B)
Neutralization of BoNT/E3 holotoxin (330 pg/mL; 20LD50/mL) by 16.5 nM scFv of ELC18 and ELC51. Successful neutralization resulted in a longer 50%
paralysis time of the hemidiaphragm at the same dose of toxin. As a control, a hemidiaphragm preparation exposed only to Krebs, without toxin, was used.
Each data set is from a single hemidiaphragm preparation.
doi:10.1371/journal.pone.0139905.g003
Fig 4. Ex vivomouse phrenic nerve-hemidiaphragm assay with ELC18. A) Neutralization of BoNT/E3 holotoxin (330 pg/mL; 20LD50/mL) by different
concentrations of ELC18. Neutralization properties of ELC18 as scFv at 165 nM, 16.5 nM, 3.3 nM, and 0.3 nM were evaluated. B) Neutralization properties of
ELC18 as scFv-Fc at 9.4 nM, 4.7 nM, and 0.9 nM were evaluated. Each neutralization set is from a single hemidiaphragm preparation per concentration.
doi:10.1371/journal.pone.0139905.g004
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neutralization (Table 4). At a concentration of 165 nM ELC18 and ELC51 showed a similar
neutralization efficacy with 50% paralysis time of 445 min for ELC18. The 50% paralysis time
of BoNT/E3 without antibodies (20LD50/mL) was 95 min. For further analysis the assay was
repeated with 16.5 nM scFv concentration (Fig 3B). At this concentration, only ELC18 was
neutralizing. Subsequently, only ELC18 was further analyzed at lower concentrations (Fig 4A,
Table 5). Significant neutralization (at least 25% inhibition of activity, 164 min paralysis time)
was confirmed with as low as 0.3 nM scFv ELC18, and almost 50% inhibition occurred at ~3.3
Fig 5. In vivomouse paralysis assay with ELC18 as scFv-Fc. A) The neutralization activity of ELC18 was determined in the mouse paralysis assay in
vivo. BoNT/E3 holotoxin (1LD50 per dose) was pre-mixed with each antibody at 0.064 ng, 0.32 ng, 1.6 ng, 8 ng, 40 ng, 0.2 μg and 1 μg per dose. Animals
were scored at 24 h post injection. Results are expressed as mean score for 4 mice ± SEM. Positive control group of mice were injected with BoNT/E3 toxin
alone and negative control group of mice received the maximum concentration of antibody in the absence of toxin. B) Schema of the in vivomouse paralysis
assay. Formation of abdominal ptosis after injection of botulinum neurotoxin.
doi:10.1371/journal.pone.0139905.g005
Table 3. Affinities of the four inhibiting scFv.
scFv Koff [s
−1] Kon [M
−1s−1] KD [nM]
ELC18 1.94 x 10−5 3.37 x 104 0.58
ELC51 4.37 x 10−5 4.77 x 103 9.16
ELC76 3.56 x 10−6 3.45 x 103 1.03
ELC77 1.10 x 10−5 1.16 x 105 0.01
doi:10.1371/journal.pone.0139905.t003
Table 4. Ex vivo phrenic nerve-hemidiaphragm assay. Neutralization of BoNT/E3 toxicity (20LD50/mL) by
the BoNT/E3 specific scFv ELC18, ELC51 and ELC76.
scFv 50% paralysis time [min]
ELC18 (165 nM) 445
ELC51 (165 nM) 432
ELC76 (165 nM) 210
BoNT/E3 (20LD50/mL) 95
No toxin (536*)
* Extrapolation
doi:10.1371/journal.pone.0139905.t004
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nM. This represents more favorable neutralization than inhibition in vitro, with a molar ratio
of ~1,500:1, an increase of 33-fold. For further analysis, ELC18 was converted into the scFv-Fc
antibody format and tested at different dilutions (9.4 nM, 4.7 nM and 0.9 nM) in the ex vivo
paralysis assay (Fig 4B). At the lowest concentration of 0.9 nM, a 50% paralysis time of 237
min was achieved, representing a molar ratio (scFv-Fc:toxin) of ~393:1.
In vivo neutralization of scFv-Fc against BoNT/E
The scFv-Fc form of ELC18 targeting BoNT/E-L was tested in vivo in the non-lethal mouse
flaccid paralysis protection model against pure BoNT/E3 (1LD50 per dose). Results after 24 h
are reported. A range of 6 doses of antibody, starting from 1.0 μg per dose, was used. Complete
protection was achieved with 1.6 ng of ELC18, representing a molar ratio (antibody:toxin) of
~87:1. Partial protection was observed with two further 5-fold dilutions (Fig 5).
Discussion
Botulinum neurotoxins (BoNTs) are the most toxic substances known and cause botulism, a
life-threatening disease characterized by flaccid muscle paralysis. Recombinant antibodies are
of particular interest to neutralize biological warfare agents as Bacillus anthracis, ricin or
BoNTs. They can be used for therapy and prophylaxis for personals at high exposure risk
[11,53]. To our knowledge, no recombinant human-like antibody neutralizing BoNT/E by tar-
geting the light chain (BoNT/E-L) has been reported to date. Only neutralizing antibodies tar-
geting the heavy chain of BoNT/E were described, such as 4E17 isolated from a human
immune library and targeting a conserved epitope of the BoNT translocation domain [40], or
BMR2, a single domain VHH from dromedary recognizing the binding domain of BoNT/E
[54]. In this study we focused on BoNT/E3 and described the isolation of several different scFv
which neutralized BoNT/E3 by targeting its light chain. Non-human primates are phylogeneti-
cally close to humans and their antibody sequences are similar to those in humans [55]. This is
important to ensure that any antibody isolated are well tolerated in therapeutic applications.
Macaques have been used for immunization with antigens of biodefense interest, without unto-
ward effects [56,57]. In this study, after immunization of a macaque an antibody phage display
library was constructed as previously described [37,35,31,33,38]. For immunization, only the
non-toxic recombinant light chain of BoNT/E3 was used to induce a hyper-immune response.
However, in validation of the immune response, antibody phage screening, affinity measure-
ment, in vitro, ex vivo and in vivo assays were all based on the holotoxin to ensure that only
scFv that recognize the complete toxin were selected. The constructed scFv library comprised
of 9.6 x 108 clones with a full-sized scFv insert rate of 88%, which is similar to previously pub-
lished similar studies isolating neutralizing scFv with nanomolar affinities [35,38]. Finally, 38
scFv considered as representatives of the sequence diversity were selected, then expressed in E.
coli and tested in the SNAP–25 endopeptidase assay [49]. Four scFv were identified, that inhib-
ited the endopeptidase activity of BoNT/E3 in vitro. The best way to compare the inhibitory
Table 5. Ex vivo phrenic nerve-hemidiaphragm assay. Neutralization of BoNT/E3 toxicity (20LD50/mL) by
the BoNT/E3 specific ELC18 as scFv at different concentrations.
ELC18 (scFv) 50% paralysis time [min]
165 nM 445
16.5 nM 290
3.3 nM 291
0.3 nM 164
doi:10.1371/journal.pone.0139905.t005
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effectiveness of these antibodies is to use the molar ratio of antibody to toxin at which 50%
inhibition was observed. ELC76 was the most effective scFv with an IC50value of 33.8 nM and a
molar ratio of 14,765:1 (scFv:toxin). Affinity of the four endopeptidase-inhibiting scFv was
measured by surface plasmon resonance. ELC77 had the highest affinity, 0.01 nM, whereas the
affinity of ELC18 was 0.58 nM. For a more realistic evaluation of the antibodies an assay that
addresses their neutralization capacity was needed. Here, the ex vivomouse phrenic nerve-
hemidiaphragm assay was chosen. This ex vivo assay is closely mimicking the in vivo respira-
tory paralysis caused by BoNTs [51] and ex vivo neutralization assessments highly correlated
with those of the in vivo assay for assessment of the neutralization activity of polyclonal anti-
bodies against BoNT serotypes A, B and E [52]. The most effective neutralization was achieved
with ELC18, with neutralization at a molar ratio of ~1,500:1. This is about 33-times more
favorable than in vitro inhibition of light chain activity. There was, no relationship between
affinity, neutralization capacity and IC50 inhibition, indicating that the selected antibodies
bind to different epitopes. Compared to scFv, IgG has a higher steric hindrance, so that con-
verting the scFv to full-length IgG should improve the IC50 value and the molar ratio. As an
example, the molar ratio for 2H8, an scFv antibody neutralizing BoNT/A1 (20LD50/mL) in a
similar endopeptidase assay to that used here by targeting the light chain, was 64,000:1 (scFv:
toxin). After converting 2H8 into a scFv-Fc format, a bivalent antibody similar to IgG, 50%
inhibition was observed at a molar ratio of 6,500:1 (scFv-Fc:toxin) [38]. After conversion into
scFv-Fc, ELC18 was effective at neutralizing BoNT/E3 in the ex vivo assay at 0.9 nM, represent-
ing a molar ratio of ~393:1, an improvement on the scFv. More importantly, when tested in
vivo ELC18 scFv-Fc was protective at 1.6 ng/dose against 1LD50 BoNT/E3, representing a
molar ratio of only ~87:1.
For further therapeutic development, ELC18 should be validated as IgG in lethal assays. IgG
4E17.1, an affinity matured variant of 4E17, protected mice challenged with 200LD50/mL of
BoNT/E at a single dose of 25 μg IgG [40]. Unlike scFv produced in bacterial cells, mammalian
cells that are known to glycosylate protein, so that any glycosylation of the variable region of
IgG produced in such cells could hinder antigen binding. ELC77 was predicted to be glycosy-
lated from its sequence and was therefore discarded from further development, to avoid any
decrease in affinity or in neutralization capacity after expression as full length IgG in an
eukaryotic system. For human treatment, the potential immunogenicity of a recombinant anti-
body is of concern. It is considered that more human-like antibodies are well tolerated, because
they should be considered as a part of the immunological-self [55,58,59]. Nevertheless, to limit
the risk, several tools have been developed to predict antibody tolerance. One possibility to esti-
mate the potential immunogenicity of non-human antibodies is to calculate the level of iden-
tity, given by the Germinality Index (GI), which compares the corresponding framework
regions with the most similar human germline encoding framework regions [36]. The GI indi-
rectly predicts the tolerance of the corresponding variable regions, based on the assumption
that germline encoding sequences are optimally tolerated, as they represent part of the IgM
repertoire. Out of the three neutralizing scFv, ELC76 was the most human-like antibody frag-
ment with a mean GI value of 91.2% (87.9% for VH and 94.4% for VL) followed by ELC18
with 87.8% (85.7% for VH and 89.9% for VL). For comparison, the average GI value of 500
scFv isolated from the human naïve antibody gene library HAL7/8 [60] was 95.7%. The high
humanness of the antibodies isolated against BoNT/E3 predict a high tolerance and studies
with the chimeric antibody lumiliximab, consisting of the variable regions of a macaque anti-
body in combination with the human constant regions, showed a good immune tolerance in
human [61,62]. As an alternative, germline humanization of antibodies provides a potentially
promising method for increasing immune tolerance for human treatment [63]. This method
was successfully used for the humanization of 35PA38, a scFv neutralizing the anthrax lethal
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toxin, isolated from a macaque immune library and this increased its GI value to 97.8% [64].
For further development, germline humanization of the BoNT/E3 specific antibodies reported
here would be a reasonable strategy. The antibody ELC18 is a promising candidate for future
therapeutic development.
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